DES Study Results Provoke SIRIUS Flurry Of Correspondence
This article was originally published in The Gray Sheet
Executive Summary
Drug-eluting stents should be compared with off-pump coronary bypass surgery in a randomized trial for patients with high-risk lesions, according to Johnson & Johnson (Cypher) SIRIUS study lead investigators
You may also be interested in...
Cordis Counters TAXUS IV With “New SIRIUS,” Critiques Angiographic Data
The revascularization rates associated with Boston Scientific's Taxus paclitaxel-eluting stent in TAXUS IV are "artificially" depressed by the relatively low rate of angiographic follow-up in the trial, according to rival Johnson & Johnson/Cordis
Drug-Eluting Stent Enthusiasts Concede CABG Revenue Loss For Hospitals
Cardiovascular interventionalists and analysts agree that 10-20% of U.S. coronary revascularization procedures will shift each year from coronary artery bypass graft (CABG) to drug-eluting stents
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.